EX-23.1 28 g06286exv23w1.htm EX-23.1 CONSENT OF KPMG LLP

#####

EXHIBIT 23.1
Consent of Independent Registered Public Accounting Firm
The Board of Directors
Cumberland Pharmaceuticals, Inc.:
We consent to the use of our report included herein and to the reference to our firm under the heading “Experts” in the prospectus. Our report refers to a change in accounting for stock-based compensation in 2006.
Nashville, Tennessee
May 1, 2007